Half-year report · HY
4564.TEDINET S100X054
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥432m | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥225m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥476m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥531m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥494m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥554m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥289m | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥426m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥834m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥834m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥525m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥579m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥61m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥279,000 | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.89 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.18 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥185m |
| Cancer Precision Medical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥284m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | −¥291m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥178m |
| Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥94m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥259m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥353m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 400
| Item | Context | Value | Unit |
|---|---|---|---|
| Gain on reversal of subscription rights to shares ope cf | Prior1InterimDuration | -550000 | JPY |
| Gain on reversal of subscription rights to shares ope cf | InterimDuration | -550000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1InterimDuration | -8437000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | InterimDuration | 53891000 | JPY |
| Decrease increase in inventories ope cf | Prior1InterimDuration | -114962000 | JPY |
| Decrease increase in inventories ope cf | InterimDuration | -12941000 | JPY |
| Decrease increase in advance payments ope cf | Prior1InterimDuration | -19014000 | JPY |
| Decrease increase in advance payments ope cf | InterimDuration | 27005000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | Prior1InterimDuration | -28224000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | InterimDuration | -13356000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1InterimDuration | 64011000 | JPY |
| Increase decrease in accounts payable other ope cf | InterimDuration | -35100000 | JPY |
| Increase decrease in contract liabilities ope cf | Prior1InterimDuration | -68652000 | JPY |
| Increase decrease in contract liabilities ope cf | InterimDuration | -141707000 | JPY |
| Increase decrease in income taxes payable the factor based tax ope cf | Prior1InterimDuration | 73130000 | JPY |
| Increase decrease in income taxes payable the factor based tax ope cf | InterimDuration | 76996000 | JPY |
| Other net ope cf | Prior1InterimDuration | 55357000 | JPY |
| Other net ope cf | InterimDuration | -1500000 | JPY |
| Subtotal ope cf | Prior1InterimDuration | -575685000 | JPY |
| Subtotal ope cf | InterimDuration | -522255000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -655000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -655000 | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -2425000 | JPY |
| Income taxes paid ope cf | InterimDuration | -2160000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | -578766000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | -525071000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | － | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -60967000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | － | JPY |
| Net cash provided by used in investment activities | InterimDuration | -60967000 | JPY |
| Payments for long term accounts payable other fin cf | Prior1InterimDuration | -27817000 | JPY |
| Payments for long term accounts payable other fin cf | InterimDuration | -27855000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1InterimDuration | 1174772000 | JPY |
| Proceeds from issuance of common stock fin cf | InterimDuration | 1449563000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | Prior1InterimDuration | 3780000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | InterimDuration | 5670000 | JPY |
| Repayments to share acquisition rights fin cf | Prior1InterimDuration | -1350000 | JPY |
| Repayments to share acquisition rights fin cf | InterimDuration | － | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | 1149384000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | 1427378000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 570617000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 841340000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 527656000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 833883000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 1098274000 | JPY |
| Cash and cash equivalents | InterimInstant | 1675223000 | JPY |
| Taxes and dues sga | Prior1InterimDuration | 76322000 | JPY |
| Taxes and dues sga | InterimDuration | 81171000 | JPY |
| Commission fee sga | Prior1InterimDuration | 46320000 | JPY |
| Commission fee sga | InterimDuration | 50024000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |